{"id":5858,"date":"2024-11-07T08:14:58","date_gmt":"2024-11-07T14:14:58","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5858"},"modified":"2025-06-27T11:04:05","modified_gmt":"2025-06-27T16:04:05","slug":"renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","title":{"rendered":"El reconocido cirujano de retina y empresario m\u00e9dico Sunil Gupta, MD, se une a la junta directiva de Nanoscope"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5858\" class=\"elementor elementor-5858\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7336a5c0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7336a5c0\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-46894e23\" data-id=\"46894e23\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-614fb7bc elementor-widget elementor-widget-text-editor\" data-id=\"614fb7bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\nDALLAS Nov. 7, 2024 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sunil Gupta, MD, has joined the Company&#8217;s Board of Directors. Dr. Gupta is a nationally recognized retinal surgeon and a successful entrepreneur who brings deep experience in all phases of drug development and medical devices, including commercialization and manufacturing.\n\n&#8220;Dr. Gupta possesses an extraordinary combination of medical and entrepreneurial expertise around the treatment of inherited retinal diseases and dry age-related macular degeneration. He is a renowned, patient-focused physician, as well as an effective leader in executing clinical trials and operations. Dr. Gupta has truly advanced care for retina patients across the world. He will be an invaluable member of Nanoscope&#8217;s board as we advance towards commercialization of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and dry-AMD,&#8221; said\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, Co-Founder and Chief Executive Officer of Nanoscope.\n\n&#8220;Nanoscope continues to advance work on its groundbreaking gene therapies for inherited retinal diseases such as retinitis pigmentosa (RP) and Stargardt, offering hope to patients for whom no cure currently exists,&#8221; said Dr. Gupta. &#8220;The company&#8217;s recent announcements highlighting the efficacy and safety results from its randomized Phase\u00a0<span class=\"xn-money\">2b<\/span>\u00a0trial in RP with subsequent BLA submission are revolutionary. With a Phase 3 registrational trial for Stargardt and a BLA filing in RP on the horizon, Nanoscope is closer to helping address serious unmet needs. Nanoscope has assembled a world-class team of scientists, physicians and business leaders, and I am excited to contribute.&#8221;\n\n&#8220;I want to extend a warm welcome to Dr. Gupta\u00a0and look forward\u00a0to\u00a0working with him.\u00a0He joins us at a pivotal moment in Nanoscope&#8217;s journey,&#8221; said\u00a0Glenn\u00a0Sblendorio, Chairman of the Board. &#8220;With an enhanced regulatory pathway, we look forward to utilizing his strategic expertise\u00a0as well as his network with the retinal community.&#8221;\n\nDr. Gupta is founder and clinical principal investigator at Retina Specialty Institute (RSI), one of the largest retinal research organizations in\u00a0<span class=\"xn-location\">los Estados Unidos<\/span>\u00a0serving patients in clinics across the south. He was also the founder and chief medical officer of USRetina\u2014one of the largest associations of retina physicians in\u00a0the United States specializing in drug distribution, GPO, and clinical operational processes and software development prior to its recent exit to McKesson. He founded and serves as chairman and chief medical officer of Intelligent Retinal Imaging Systems (IRIS), an FDA-cleared, cloud based, telemedicine platform for assessment of retinal eye disease in the primary care setting. Dr. Gupta&#8217;s IRIS team is working to end preventable blindness due to diabetic retinopathy and other conditions around the world. Dr. Gupta was the past chairman of the Andrews Institute Sports Medicine Center and served on the board of the Andrews Research &amp; Education Institute. In these efforts and beyond, he bridges industry and clinical care delivery organizations to optimize patient experience and outcomes. Dr. Gupta earned his medical degree from the\u00a0<span class=\"xn-org\">Universidad de Cincinnati<\/span>\u00a0Facultad de Medicina y complet\u00f3 su residencia en Oftalmolog\u00eda en el Cullen Eye Institute en\u00a0<span class=\"xn-org\">Facultad de Medicina de Baylor<\/span>\u00a0en\u00a0<span class=\"xn-location\">Houston, Texas<\/span>Complet\u00f3 una beca en Enfermedades y Cirug\u00eda V\u00edtreo-Retiniana en la Universidad de Iowa.\n\n<b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que no existe cura. El principal activo de la empresa, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, de doble ciego y controlado con placebo en los EE. UU. para la retinitis pigmentosa (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La empresa ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y recientemente\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-us-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration-302247017.html\" target=\"_blank\" rel=\"nofollow noopener\">anunci\u00f3 planes para iniciar una Fase 3<\/a>\u00a0Ensayo de registro en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.\n\n<b>Contacto de inversores:<br class=\"dnr\" \/><\/b>Socios Argot<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a>\n\nFUENTE Terap\u00e9utica del Nanoscopio\n\n<\/div>\n<\/div>\n<\/section><\/article>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS Nov. 7, 2024 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sunil Gupta, MD, has joined the Company&#8217;s Board of Directors. Dr. Gupta is a nationally recognized retinal surgeon and a successful entrepreneur who brings deep experience in all phases [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5861,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-07T14:14:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors\",\"datePublished\":\"2024-11-07T14:14:58+00:00\",\"dateModified\":\"2025-06-27T16:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\",\"name\":\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"datePublished\":\"2024-11-07T14:14:58+00:00\",\"dateModified\":\"2025-06-27T16:04:05+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El Dr. Sunil Gupta, reconocido cirujano de retina y emprendedor m\u00e9dico, se une al Consejo de Administraci\u00f3n de Nanoscope Therapeutics.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","og_locale":"es_MX","og_type":"article","og_title":"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-11-07T14:14:58+00:00","article_modified_time":"2025-06-27T16:04:05+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors","datePublished":"2024-11-07T14:14:58+00:00","dateModified":"2025-06-27T16:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/"},"wordCount":674,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","url":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","name":"El Dr. Sunil Gupta, reconocido cirujano de retina y emprendedor m\u00e9dico, se une al Consejo de Administraci\u00f3n de Nanoscope Therapeutics.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","datePublished":"2024-11-07T14:14:58+00:00","dateModified":"2025-06-27T16:04:05+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5858"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5858\/revisions"}],"predecessor-version":[{"id":9027,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5858\/revisions\/9027"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5861"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}